Anti-TAU/ MAPT/ DDPAC monoclonal antibody
Anti-TAU/ MAPT/ DDPAC antibody for FACS & in-vivo assay
Go to MAPT/MAPT products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T45593-Ab-1/ GM-Tg-hg-T45593-Ab-2 | Anti-Human MAPT monoclonal antibody | Human |
GM-Tg-rg-T45593-Ab-1/ GM-Tg-rg-T45593-Ab-2 | Anti-Rat MAPT monoclonal antibody | Rat |
GM-Tg-mg-T45593-Ab-1/ GM-Tg-mg-T45593-Ab-2 | Anti-Mouse MAPT monoclonal antibody | Mouse |
GM-Tg-cynog-T45593-Ab-1/ GM-Tg-cynog-T45593-Ab-2 | Anti-Cynomolgus/ Rhesus macaque MAPT monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T45593-Ab-1/ GM-Tg-felg-T45593-Ab-2 | Anti-Feline MAPT monoclonal antibody | Feline |
GM-Tg-cang-T45593-Ab-1/ GM-Tg-cang-T45593-Ab-2 | Anti-Canine MAPT monoclonal antibody | Canine |
GM-Tg-bovg-T45593-Ab-1/ GM-Tg-bovg-T45593-Ab-2 | Anti-Bovine MAPT monoclonal antibody | Bovine |
GM-Tg-equg-T45593-Ab-1/ GM-Tg-equg-T45593-Ab-2 | Anti-Equine MAPT monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T45593-Ab-1/ GM-Tg-hg-T45593-Ab-2; GM-Tg-rg-T45593-Ab-1/ GM-Tg-rg-T45593-Ab-2; GM-Tg-mg-T45593-Ab-1/ GM-Tg-mg-T45593-Ab-2; GM-Tg-cynog-T45593-Ab-1/ GM-Tg-cynog-T45593-Ab-2; GM-Tg-felg-T45593-Ab-1/ GM-Tg-felg-T45593-Ab-2; GM-Tg-cang-T45593-Ab-1/ GM-Tg-cang-T45593-Ab-2; GM-Tg-bovg-T45593-Ab-1/ GM-Tg-bovg-T45593-Ab-2; GM-Tg-equg-T45593-Ab-1/ GM-Tg-equg-T45593-Ab-2 |
Products Name | Anti-MAPT monoclonal antibody |
Format | mab |
Target Name | MAPT |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Diagnostic target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-MAPT benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Target information
Target ID | GM-T45593 |
Target Name | MAPT |
Gene ID | 4137,17762,29477,574327,480488,101089557,281296,100054638 |
Gene Symbol and Synonyms | DDPAC,FTDP-17,MAPT,MAPTL,MAPT_0N4R,MSTD,Mtapt,MTBT1,MTBT2,PHF-tau,PPND,PPP1R103,pTau,RNPTAU,TAU,tau-40,Tau-PHF6 |
Uniprot Accession | P10636,P19332,P57786,P29172 |
Uniprot Entry Name | TAU_HUMAN,TAU_MACMU,TAU_RAT,TAU_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Diagnostics Biomarker, INN Index |
Disease | Breast Cancer |
Gene Ensembl | ENSG00000186868 |
Target Classification | N/A |
The target: MAPT, gene name: MAPT, also named as DDPAC, FTDP-17L, MSTD, MTBT1, MTBT2, PPND, PPP1R103, TAU, MAPT. This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.